Emerging Manager Monthly

MayTech Global Riding Waves Of Technology To Growth

the accelerating pace of change and where value creation will shift with differentiated view about the obesity technological innovations has it growing disruptive inventions or service," Yin market," Yin said, noting the firm had toward a major asset milestone less than a said. decade into its journey.

Portfolio Managers Nels Wangensteen glucose monitors, a "game changing diseases like diabetes and obesity, with and Ingrid Yin, New York-based MayTech technology for diabetics," according to next generations products in the pipeline. has grown to \$850 million in assets under Wangensteen. Because of the strong management today from its launch total of link of diabetes and obesity, and Yin's which, in addition to Wangensteen and \$130 million in 2017. The firm's background separately managed accounts have also biochemistry, MayTech had long been Manager Tibor Nemes, Relationship grown to 181 from 50 over that seven-year doing research on GLP-1 drugs, a new Manager Kelli time span and is on five model delivery class of drugs now quite well-known Associate Derek Zhou and Equity platforms.

point now where our AUM growth is FDA for weight loss in the chronically analyst who had served as an intern for starting to inflect," Wangensteen said, obese in 2021. noting that the team feels great about its trajectory toward \$1 billion in assets under management.

The MayTech Global Growth Equity strategy returned 55.85% compared to 25.72% from the MSCI World Gross Index over the one-year period ending March 31, which built on outperformance over the two-, three- and five-year periods as well as a 17.59% return versus 8.46% from the benchmark since June 2008, according to the PSN Informa database.

Wangensteen noted that the firm's concentrated strategy, which is comprised of 20 to 30 names, "can generate real alpha for investors." Among MayTech's investors are the State Universities Retirement System of Illinois, which has a roughly \$42.2 million investment in the firm through emerging manager-of-managers Xponance.

The global equity manager has long believed in the transformative power technology has on life. The team's research and investments have kept it on that pulse, whether it was investments in companies focused on the digitalization of the economy, or advances in medical science, or major demographic shifts. "We combine thematic identification and deep bottom-up research. A secular theme tells us where to find growth. Once we identify an industry that's getting disrupted, we want to quantify how big the addressable market is. When we confirm it is a sustainable, long-term change, we

with a Ph.D.



"We knew the safety profile was clean with this molecule and there wasn't an effective, and safe obesity drug before GLP1. That's why the obesity market historically has been small. So, once this product was approved, we saw a validation of not only efficacy, but safety. Wegovy can help patients to lose weight by 15%, which is meaningful because it really kicks off a virtuous cycle for these patients. We really believed this market could become \$50 billion to \$100 billion in the next decade because so many people could benefit from it. Our estimate was, I think, at the time, more than ten times higher

MayTech Global Investments' focus on study the supply chain to find out than the street consensus. We did have a zeroed in on Wegovy manufacturer For years, MayTech has invested in Novo-Nordisk for investment due to its Co-founded by Managing Partners and DexCom, which makes continuous longstanding history of treating chronic

The MayTech team is also growing, in Yin, includes CCO and Operations Walker, Operations under commercial names such as Research Associate Bennett Katz. The "I feel to some extent, we're at this Wegovy, which was approved by the firm will also add another full-time the firm, according to Wangensteen.

> MayTech will also welcome a new head of distribution and a marketing associate. The firm initially started its marketing efforts with help from a third-party firm, Arrow Partners, upon launch.

> "Arrow got us known and took us around, and it was a cost-efficient way to do that," Wangensteen said. "But as we've grown, we need to bring in our own team. The institutional clients look for it to see you are making that progress."

> "We do think an internal salesperson who deeply understands our investment philosophy, process, and is able to talk about the thesis of each portfolio company with investors would provide a lot of value to prospective clients," Yin said, adding that the team encourages its sales team to participate in the morning research meetings to better assimilate themselves into the firm's investment approach.

> While MayTech continues to grow, the firm is also always searching for the next technological themes that will shape the world. Unsurprisingly, Wangensteen and Yin are high on the impact that artificial intelligence will have on the global economy moving forward. "This is the next big wave of technology, the 4th industrial revolution, and you only get a few of these in your investing lifetime," Wangensteen said. "So, you want to make sure you get it and you get it right."

> > **JUNE 2024**



MAYTECH GLOBAL INVESTMENTS

Emerging Manager Monthly

The information contained in this article is provided/distributed for informational purposes only and should not be considered investment advice or a recommendation of any particular security, strategy or investment product. The information contained in this article is accurate as of the data submitted but is subject to change.



